Bellicum Pharmaceuticals (BLCM) Stock Price, News & Analysis

Company Overview

Bellicum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company's clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen. Its clinical product candidates also include BPX-603, an autologous dual-switch GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing human epidermal growth factor receptor 2 antigen. It has collaboration and license agreements with Adaptimmune Therapeutics plc; Agensys, Inc.; BioVec Pharma, Inc.; ARIAD Pharmaceuticals, Inc.; and Baylor College of Medicine. Bellicum Pharmaceuticals, Inc. was incorporated in 2004 and is based in Houston, Texas.

Key Stats

• Today's Range: $0.07 to $0.09
• 50-Day Range: $0.07 to $0.10
• 52-Week Range: $0.06 to $1.31
• Volume: 6,059 shs
• Average Volume: 22,874 shs
• Market Capitalization: $726.57 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

BLCM Stock Analysis - Frequently Asked Questions

How were Bellicum Pharmaceuticals' earnings last quarter?

Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) released its earnings results on Wednesday, August, 11th. The biopharmaceutical company reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.37) by $1.15. The biopharmaceutical company earned $0.70 million during the quarter.

When did Bellicum Pharmaceuticals' stock split?

Bellicum Pharmaceuticals shares reverse split on Thursday, February 6th 2020.The 1-10 reverse split was announced on Wednesday, February 5th 2020. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, February 5th 2020. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

When did Bellicum Pharmaceuticals IPO?

Bellicum Pharmaceuticals (BLCM) raised $101 million in an initial public offering on Thursday, December 18th 2014. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. Jefferies, Citigroup and Piper Jaffray acted as the underwriters for the IPO and Trout Capital was co-manager.

What other stocks do shareholders of Bellicum Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Bellicum Pharmaceuticals investors own include Arrowhead Pharmaceuticals (ARWR), Alliance Resource Partners (ARLP), AVEO Pharmaceuticals (AVEO), NVIDIA (NVDA), CyberArk Software (CYBR), Gilead Sciences (GILD) and Bristol Myers Squibb (BMY).

Company Calendar

• Last Earnings: 8/11/2021
• Today: 7/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: NASDAQ:BLCM
• CIK: 1358403
• Web: www.bellicum.com
• Phone: (281) 454-3424
• Fax: N/A
• Employees: 13
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$24.97 million
• Net Margins: N/A
• Pretax Margin: -1,492.40%
• Return on Equity: N/A
• Return on Assets: -157.93%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.04
• Quick Ratio: 3.04

Sales & Book Value

• Annual Sales: $1.50 million
• Price / Sales: 0.48
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.23 per share
• Price / Book: 0.33

Miscellaneous

• Outstanding Shares: 9,720,000
• Free Float: 8,716,000
• Market Cap: $726.57 thousand
• Optionable: Not Optionable
• Beta: 1.39